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Abstract	1 
	2 
Conditions	of	 relative	humidity	and	temperature	 inside	 the	 lungs	are	generally	very	different	 from	3 
the	 outside	 air,	 with	 the	 lung	 environment	 typically	 being	 warmer	 and	 of	 higher	 humidity.	 The	4 
change	in	temperature	and	humidity	as	pharmaceutical	drugs	pass	from	inhaler	to	lung	environment	5 
can	cause	hygroscopic	phase	transitions	and	particle	growth.		This	implies	that	inhalable	drugs	that	6 
do	 not	 exhibit	 hygroscopic	 properties	 under	 standard	 laboratory	 testing	 may	 behave	 differently	7 
inside	 the	 human	 body.	 To	 better	 examine	 these	 properties,	 solid	 particles	 injected	 directly	 from	8 
four	 different	 pressurised	 metered	 dose	 inhalers	 were	 stably	 captured	 in	 an	 optical	 trap	 and	9 
examined	online	via	Raman	spectroscopy.	Micron-sized	particles	of	salmeterol	xinafoate,	fluticasone	10 
propionate	and	ciclesonide	were	suspended	and	examined	at	a	range	of	relative	humidity	conditions	11 
inside	 a	 chamber	 designed	 to	mimic	 conditions	 inside	 the	 respiratory	 tract	 and	 lung.	 Particles	 of	12 
salbutamol	 sulfate	 were	 also	 examined	 under	 different	 temperature	 and	 relative	 humidity	13 
conditions	 to	 explore	 the	 effect	 of	 temperature	 upon	 their	 hygroscopicity.	 This	 technique	 allows	14 
inhalable	 drugs	 with	 hygroscopic	 properties	 to	 be	 tested	 to	 ensure	 that	 they	 are	 still	 within	 the	15 
optimum	size	range	for	retention	within	the	lungs	post	inhalation.	16 
1. Introduction	17 
1.1	Respiratory	drugs	and	drug	delivery	18 
Respiratory	ailments	in	the	form	of	asthma	and	Chronic	Obstructive	Pulmonary	Disease	(COPD)	are	19 
managed	 with	 inhalable	 drugs.	 These	 drugs	 include	 beta-2	 agonists	 such	 as	 salbutamol	 and	20 
salmeterol,	and	corticosteroids	like	fluticasone	and	ciclesonide.	21 
Salbutamol	sulfate	and	salmeterol	xinafoate	are	both	beta-2	andrenoceptor	agonists,	meaning	that	22 
they	target	the	beta-2	receptors	in	bronchial	muscle	cells	in	a	similar	manner	to	adrenaline	(Reisine,	23 
et	 al.,	 1983),	 forcing	 calcium	 out	 of	 the	 cells	 thus	 forcing	 them	 to	 relax,	 and	 opening	 the	 user’s	24 
airways	to	allow	easier	breathing.	Salbutamol	(Ventalin™,	Salamol™)	has	been	a	popular	treatment	25 
for	asthma	and	COPD	since	1968	(Icha,	2007),	while	Salmeterol	(Serevent™)	was	introduced	in	1988	26 
as	a	longer	lasting	alternative	(Ullman	&	Svedmyr,	1988).	27 
Fluticasone	propionate	 (Flixotide™)	 is	 an	 artificial	 corticosteroid	 that	 assists	 breathing	by	 reducing	28 
inflammation	 in	 the	 lung	 lining	 (Harding,	1990).	Whilst	 steroids	are	useful	 in	managing	 respiratory	29 
conditions,	 deposition	 of	 the	 drug	 in	 the	 oropharynx	 suppresses	 the	 local	 immune	 system,	 and	30 
patients	often	suffer	from	mouth	and	throat	infections	such	as	oral	candidiasis	as	a	result	(Lee,	et	al.,	31 
2012),	 (Renner,	et	al.,	2012).	Fluticasone	propionate	 is	also	supplied	as	a	combination	 inhaler	with	32 
salmeterol	 xinafoate	 (Seretide™)	 due	 to	 their	 complementary	 modes	 of	 action	 (Woolcock,	 et	 al.,	33 
1996)	(Chapman,	et	al.,	1999)	(Calverley,	et	al.,	2003).	Pure	compounds	rather	than	mixtures	were	34 
used	in	this	study.	35 
Ciclesonide	 (Alvesco™)	 is	 a	 recently	 developed	 inhaled	 corticosteroid	 used	 as	 a	 treatment	 for	36 
asthma,	 hay	 fever	 and	 other	 respiratory	 ailments.	 In	 order	 to	 reduce	 the	 mouth	 and	 throat	37 
infections	associated	with	 respiratory	 steroid	application,	 ciclesonide	 is	designed	 to	be	biologically	38 
inactive	until	 it	 interacts	with	esterase	enzymes	present	 in	 the	 lung	 (Mutch,	et	al.,	2007)	at	which	39 
point	 it	 is	hydrolysed	to	the	active	 form	desisobutyryl-ciclesonide;	 these	enzymes	are	not	 found	 in	40 
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the	oral	cavity	to	the	same	extent,	and	hence	the	potential	benefit	of	 reduced	oropharyngeal	side	1 
effects.		2 
Inhalable	 drugs	 are	 predominately	 administered	 by	 nebuliser,	 dry	 powder	 inhaler	 (DPI)	 or	 by	3 
pressurised	 metered	 dose	 inhaler	 (pMDI).	 Powered	 nebulisers	 have	 been	 in	 use	 since	 the	 19th	4 
century	(Sanders,	2007),	while	cheaper	and	more	portable	pMDIs	were	invented	in	1955	(Purewal	&	5 
Grant,	1997).	The	ban	on	CFC	propellants	following	the	introduction	of	the	Montreal	Protocol	(UNEP,	6 
1987)	did	not	include	pMDIs	due	to	their	medical	necessity,	but	the	move	away	from	CFCs	did	result	7 
in	a	rapid	expansion	of	DPI	devices	as	an	alternative	to	pMDIs	 (Clark,	1994).	However,	DPI	devices	8 
typically	require	a	greater	patient	inhalation	effort	in	order	to	disaggregate	the	powder	bed,	making	9 
them	unsuitable	for	patients	with	severe	respiratory	disease.	Providing	patients	are	correctly	trained	10 
on	coordinating	actuation	and	inhalation,	pMDI	devices	overcome	the	disadvantages	of	DPI	devices,	11 
and	the	pMDI	is	now	the	most	popular	device	for	delivering	drugs	to	the	human	respiratory	system	12 
in	Britain	(Lavorini,	et	al.,	2011).	While	nebulisers	were	believed	to	be	more	effective	than	pMDIs	in	13 
delivering	 bronchodilator	 drugs,	 a	 double-blind	 clinical	 study	 found	 them	 to	 be	 no	more	 effective	14 
than	 simpler,	 cheaper	pMDIs	with	 spacers	designed	 for	use	with	babies	 and	 toddlers,	 the	hardest	15 
age	group	to	administer	inhalable	drugs	to	(Delgado,	et	al.,	2003).	16 
Modern	 pMDIs	 contain	 solid	 drug	 particles	which	 are	 suspended	 in	 a	 liquefied	 hydrofluoroalkane	17 
propellant:	most	commonly	HFA-134a	(Cripps,	et	al.,	2000)	(Leach,	2005).	Other	co-solvents	such	as	18 
ethanol	or	oleic	acid	can	be	used	depending	on	the	drug	(Bell	&	Newman,	2007).	The	solvent	rapidly	19 
evaporates	at	ambient	temperature	upon	activation	of	the	pMDI,	generating	a	fixed	dose,	inhalable	20 
aerosol	 of	micron-sized	 solid	drug	particles	 travelling	 at	 a	wide	 range	of	 planar	 velocities	 into	 the	21 
user’s	trachaea	and	lungs	(Crosland,	et	al.,	2009).	22 
1.2	Significance	of	relative	humidity	and	temperature	on	delivery	efficiency	23 
Drugs	acting	within	the	respiratory	tract	are	only	effective	if	the	particle	aerodynamic	diameters	are	24 
in	the	1-5µm	range	since	larger	particles	cannot	reach	the	receptor	sites	inside	the	lungs	(Labiris	&	25 
Dolovich,	2003).	Hygroscopic	particles	can	change	size	as	they	collect	water	from	the	air	(Broday	&	26 
Georgopoulos,	2001)	which	means	that	particles	manufactured	in	the	correct	size	range	may	be	too	27 
large	to	be	effective	by	the	time	they	reach	the	lungs.	28 
Previous	 work	 has	 shown	 (Tong,	 et	 al.,	 2014)	 that	 salbutamol	 sulfate	 deliquesces	 at	 around	 92%	29 
relative	humidity	(RH).	Deliquescence	describes	the	phase	change	of	a	crystalline	solid	to	a	saturated	30 
solution	 droplet	 using	water	 condensed	 from	 the	 surrounding	 air.	 Temperature	 can	 affect	 the	RH	31 
level	required	to	bring	about	deliquescence	in	hygroscopic	substances	but	the	effect	varies	between	32 
compounds	(Lipasek,	et	al.,	2013).	Temperature	also	has	a	significant	 influence	over	the	saturation	33 
water	vapour	pressure	of	air	(Lawrence,	2005)	so	the	air	inside	the	lungs	at	37oC	and	near-100%	RH	34 
contains	three	times	the	concentration	of	water	as	outside	air	at	similar	RH	and	20oC	(Nave,	2004).	35 
However,	 temperature	 influences	 the	 kinetics	 of	 drug	 dissolution	 only,	 rather	 than	 the	36 
thermodynamic	 behaviour	 of	 solid	 particles,	 which	 remain	 relatively	 unchanged,	 and	 it	 is	 not	37 
expected	to	significantly	impact	hygroscopic	properties.	38 
The	rate	of	deliquescence	dictates	the	rate	of	adsorption	of	drugs	across	lung	epithelia,	since	a	given	39 
drug	cannot	be	absorbed	until	it	has	fully	dissolved	(Bikiaris,	2011).	This	lends	a	time-critical	aspect	40 
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to	 drug	 delivery	 since	 solid	 particles	 in	 the	 lungs	 are	 removed	 over	 time	 by	 macrophage	 and	1 
mucociliary	activity	(Hardy	&	Chadwick,	2000).	If,	for	example,	80%	of	a	given	drug	is	removed	in	this	2 
manner	before	it	can	perform	its	function,	 five	times	the	dose	must	be	administered	and	resultant	3 
side	 effects	 such	 as	 immunosuppression	with	 corticosteroids	 (Lee,	 et	 al.,	 2012)	 and	hypoalkaemia	4 
with	salbutamol	(Hung,	et	al.,	1999)	have	a	greater	impact	on	patient	health.	On	the	other	hand,	as	5 
mentioned	 in	the	previous	section	rapid	deliquescence	can	 lead	to	an	 increase	 in	particle	size	that	6 
makes	it	more	difficult	for	drugs	to	reach	deep	enough	into	the	airways.	Finding	optimal	values	for	7 
both	 particle	 size	 and	 hygroscopicity	 is	 essential	 to	 providing	 patients	 with	 the	 most	 effective	8 
treatment	with	the	least	side	effects,	and	is	the	primary	motivation	for	this	series	of	experiments.	9 
Investigations	 are	 ongoing	 into	 the	 hygroscopic	behaviour	 of	 drug	 aerosols	 delivered	by	 nebuliser	10 
(Haddrell,	 et	 al.,	 2014).	 However,	 the	 popularity	 of	 pMDI	 delivery	 for	 bronchodilation	medication	11 
and	 the	 logistical	 difficulties	 involved	 in	 modelling	 the	 pharmacokinetic	 behaviour	 of	 medication	12 
inside	the	lung	of	a	living	creature	mean	that	similar	studies	on	pMDI-delivered	drugs	are	justified.		13 
This	 series	 of	 experiments	 investigates	 the	 use	 of	 an	 optical	 trap	 to	 stably	 levitate	 drug	 aerosols	14 
released	by	popular	pMDI	devices.	The	set	up	allows	for	the	control	of	temperature	and	RH	to	more	15 
closely	mimic	the	human	lung	than	conventional	cover	slip	analysis.	16 
2. Methods	and	Materials	17 
The	combination	of	optical	trap,	Raman	spectroscopy	and	model	lung	was	first	described	in	Tong	et	18 
al	 2014	 (Tong,	 et	 al.,	 2014).	 	 The	 optical	 trap	 uses	 a	 counter	 propagating	 dual	 beam	 (CPDB)	 trap	19 
configuration	 first	 described	 by	 Rkiouak	 et	 al.	 (Rkiouak,	 et	 al.,	 2014)	 and	 deployed	 in	 several	20 
subsequent	experiments	(Tang,	et	al.,	2014)	(Jones,	et	al.,	2015)	(Hunt,	et	al.,	2015).	 	This	trapping	21 
setup	 is	 remarkable	 because	 it	 is	 capable	 of	 stably	 trapping	 micron-sized	 solid	 particles	 of	 non-22 
spherical	geometry	for	periods	of	time	up	to	several	hours.	23 
2.1	Counter	propagating	dual	beam	optical	trap	24 
The	 trapping	 beams	 were	 generated	 by	 a	 1064nm	 Nd:Yag	 laser	 (Ventus,	 Laser	 Quantum)	 passed	25 
through	a	beam	splitter	(Oz	optics)	and	fibre-coupled	into	two	single-mode	fibres.		Each	fibre	output	26 
was	delivered	 to	beam	expansion	and	collimation	optics	before	entering	 the	objective	 lenses.	The	27 
laser	 power	 at	 output	 was	 15mW	 from	 the	 top	 objective	 lens	 and	 10mW	 through	 the	 bottom	28 
objective	lens	[fig	2].	The	asymmetry	in	power	ensured	that	trapped	particles	were	driven	closer	to	29 
the	optical	focus	plane	of	the	bottom	objective	through	which	the	Raman	laser	is	passed,	ensuring	30 
better	 focus	on	 the	 resulting	 images	 (Rkiouak,	et	al.,	2014).	The	 foci	of	 the	 lasers	were	positioned	31 
~10µm	apart,	which	created	a	trapping	volume	large	enough	to	stably	hold	1-5µm	particles	for	long	32 
periods.	Once	all	useful	observations	had	been	collected	 from	a	 trapped	particle,	 the	particle	was	33 
allowed	to	fall	under	gravity	to	the	cover	slip	by	blocking	the	1064nm	trapping	beams.	34 
There	are	several	reasons	to	prefer	an	optical	trap	to	cover	slip	analysis.	The	most	significant	is	that	35 
pharmaceutical	aerosols	are,	until	they	reach	the	respiratory	tract,	suspended	particles	and	attempts	36 
to	 recreate	 their	 conditions	 should	 be	 as	 close	 as	 possible.	 Interactions	 between	 collecting	37 
substrates	and	water	can	measurably	alter	the	deliquescence	point	of	hygroscopic	particles	(Eom,	et	38 
al.,	2014)	with	hydrophobic	surfaces	like	glass	reducing	the	deliquescence	point	of	sodium	chloride	39 
by	1.5%	compared	to	a	suspended	particle.	Any	particle	landing	on	a	cover	slip	will	have	part	of	its	40 
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surface	 in	 contact	 with	 the	 slip	 rather	 than	 exposed	 to	 the	 surrounding	 air	 [see	 figure	 1],	 so	 a	1 
hygroscopic	particle	will	form	a	water	layer	beginning	with	a	halo	around	the	contact	point	with	the	2 
cover	 slip	 rather	 than	 across	 the	 surface	 dictated	 by	 the	 particle’s	 geometry	 and	 density	 of	3 
hygroscopic	sites.	The	shape	of	the	resulting	droplet	and	rate	of	adsorption	will	both	be	affected	by	4 
the	presence	of	a	cover	slip.	5 
 6 
Figure 1. An illustration of the influence of coverslips on the formation of water layers on 7 
hygroscopic particles 8 
This	is	especially	important	in	time-critical	experiments	such	as	those	reported	in	this	paper.	Optical	9 
trapping	 represents	 the	 best	 current	 option	 for	 making	 detailed	 observations	 of	 physical	 and	10 
chemical	 changes	 on	 suspended	 particles	 in	 varying	 conditions,	 and	 yields	 better	 resolved	 Raman	11 
spectra	 than	particles	observed	on	a	cover	 slip	due	 to	 the	 removal	of	 interfering	 spectral	 features	12 
associated	with	 the	 composition	 of	 the	 cover	 slip.	 	 Optical	 trapping	 is	 superior	 for	 single	 particle	13 
spectroscopy	when	compared	to	other	single	particle	levitation	techniques,	such	as	electrodynamic	14 
balances	 or	 acoustic	 trapping,	 because	 the	 optical	 setup	 ensures	 good	 alignment	 between	 the	15 
studied	particle	and	spectroscopic	probe	(Hargreaves,	et	al.,	2010).	16 
Optical	trapping	is	easiest	with	spherical	or	spheroidal	particles	and	droplets	due	to	their	symmetry	17 
(Ashkin,	 1992).	 While	 the	 setup	 used	 in	 this	 work	 has	 demonstrated	 the	 capacity	 to	 trap	 non-18 
spherical	 particles	 for	 periods	 of	 an	 hour	 or	 longer	 (Rkiouak,	 et	 al.,	 2014)	 (Tong,	 et	 al.,	 2014),	19 
particles	that	are	closer	to	spheres	are	still	easier	to	trap	for	the	same	reasons.	20 
2.2	Raman	Spectroscopy	21 
Raman	spectroscopy	is	a	powerful	technique	for	examining	the	functional	groups	and	intermolecular	22 
interactions	 of	 substances,	 requiring	 very	 small	 sample	 masses	 and	 no	 sample	 preparation	23 
(Hirschfeld	 &	 Chase,	 1986)	 (Vankeirsbilck,	 et	 al.,	 2002)	 and	 making	 it	 ideal	 for	 the	 analysis	 of	24 
micrometer-scale	 drug	 particles.	 Raman	 spectroscopy	 has	 much	 lower	 signal-to-noise	 ratio	 than	25 
competing	 infrared	analysis	 techniques	because	of	the	visible	range	detection	region,	and	because	26 
the	scattering	wavelengths	are	separate	from	those	of	the	excitation	laser,	so	the	technique	can	be	27 
effective	with	very	 small	 samples	whose	absorption	would	be	 indistinguishable	against	a	 standard	28 
FT-IR	 beam	 (PerkinElmer	 Inc,	 2008).	 These	 experiments	 use	 a	 Raman	 setup	 which	 collects	 back-29 
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scattered	photons	along	the	same	path	as	 the	excitation	 laser,	but	 filtering	 the	excitation	photons	1 
with	a	Razoredge	dichroic	mirror	and	longpass	edge	filter	combination	(SemRock)	(Figure	2b).	2 
Raman	 scattering	 was	 generated	 using	 a	 514.5nm	 Ar-ion	 laser	 (Innova	 300C,	 Coherent),	 with	 a	3 
power	of	4.3mW	measured	at	the	laser	focus.	Each	Raman	spectrum	was	generated	by	a	30	second	4 
exposure	 to	 the	 514.5nm	 laser.	 These	 wavelength	 and	 power	 settings	 were	 selected	 based	 on	5 
previous	experiments	(Hunt,	et	al.,	2013)	as	they	were	found	to	cause	minimal	heating	of	samples	6 
over	 long	periods	of	exposure.	 It	 is	known	that	organic	molecules	with	multiple	conjugated	double	7 
bonds	 can	 fluoresce	 when	 exposed	 to	 UV-visible	 light	 frequencies	 (Sauer,	 et	 al.,	 2011)	 and	 this	8 
fluorescence	can	saturate	the	comparatively	weak	Raman	scattering	signal	(Huang,	et	al.,	2003).	This	9 
effect	is	discussed	in	section	3.2d.	Raman	scattered	light	was	collected	in	the	region	of	540-1830	cm-10 
1.	11 
Wavelength	 calibration	of	 the	Raman	 spectrometer	was	 carried	 out	 using	 a	 cover	 slip	with	 raised	12 
sides	containing	pure	liquid	toluene.	The	position	of	spectral	peaks	for	toluene	is	well	characterized	13 
and	these	are	used	as	a	reference	for	wavelength	calibration.	14 
2.3	Artificial	Lung	Chamber	&	Particle	Imaging	15 
 16 
Figure 2 Top-down (A) and side (B) views of the artificial lung chamber  17 
(High RH conditions here defined as >93% @ 20oC) 18 
The	artificial	lung	(figure	2)	was	an	aluminium	chamber	of	internal	dimensions	approximately	10	x	2	19 
x	1cm,	with	borosilicate	cover	slip	windows	at	the	top	and	bottom	to	admit	laser	light	and	also	at	the	20 
sides	 to	 observe	 particles	 using	 a	 Mitutoyo	 M	 Plan	 Apo	 20x	 objective	 lens	 connected	 to	 a	 CCD	21 
camera	(Princeton	Instruments,	Spec10),	opposite	an	LED	source	(Comar	Optics).	A	monitor	attached	22 
to	the	CCD	camera	allowed	users	to	observe	particles	passing	around,	through	and	into	the	optical	23 
trap.	24 
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Relative	Humidity	(RH)	and	temperature	were	monitored	using	a	Sensirion	SHT-75	RH	probe	with	a	1 
manufacturer-stated	 accuracy	 of	 ±1.8%	 RH	 and	 ±0.3oC.	 Raman	 spectra	 were	 collected	 within	 3	2 
minutes	 of	 reaching	 the	 desired	 RH.	 RH	 levels	were	 altered	 using	N2	 gas	 sourced	 from	 boiled	 off	3 
liquid	 nitrogen,	 using	 a	 flow	 rate	 of	 ~200	 cm3/min	 through	 a	 Bronkhorst	 MV-301	 mass	 flow	4 
controller.	A	lower	flow	rate	of	100	cm3/min	was	used	for	RH	adjustment	of	the	Salmeterol	particles,	5 
since	 higher	 flow	 rates	 tended	 to	 dislodge	 the	 particles	 from	 the	 trap	 for	 reasons	 discussed	 in	6 
section	 3a.	 The	 input	 and	 exhaust	 ports	 were	 located	 on	 the	 same	 face	 of	 the	 cell	 in	 order	 to	7 
generate	 slow	 flow	 conditions	 around	 trapped	 particles	 and	 thus	minimise	 turbulence	 that	might	8 
dislodge	the	particle.	9 
The	gas	was	either	run	into	the	cell	directly	(low	RH)	or	passed	through	a	bubbler	containing	milli-Q	10 
grade	 deionized	 water	 before	 entering	 the	 cell	 (high	 RH).	 For	 very	 high	 RH	 conditions,	 a	 water	11 
reservoir	 was	 added	 inside	 the	 chamber.	 While	 the	 bubbler	 could	 provide	 RH	 up	 to	 ~90%,	 the	12 
reservoir	could	generate	RH	as	high	as	93%	at	30oC	and	up	to	98%	at	20oC.		13 
Salmeterol,	fluticasone	and	ciclesonide	were	analysed	at	ambient	temperature	at	high	and	low	RH.	14 
Salbutamol	sulfate	was	analysed	both	at	ambient	temperature	and	at	more	physiologically	relevant	15 
temperatures	 by	 incubation	 of	 the	 microscope	 environment	 using	 Solent	 Scientific	 incubator	16 
components.	17 
2.4	pMDI	injection	18 
To	dispense	the	aerosolised	drug	 into	the	artificial	 lung	chamber,	a	simple	connector	was	built	 for	19 
the	 pMDI	 outlet	 involving	 a	 flexible	 rubber	 cap	 with	 a	 rigid	 6mm	 (internal	 diameter)	 PTFE	 tube	20 
protruding	through	it.	The	tube	was	connected	to	a	similar	tube	on	the	side	of	the	artificial	lung	by	a	21 
short	 length	of	flexible	silicone	tubing.	The	funnel	was	washed	sequentially	 in	deionized	water	and	22 
methanol	to	minimise	potential	cross-contamination	with	other	drugs.	23 
The	propellant	flow	within	the	sample	chamber	carried	material	from	each	pMDI	discharge	into	the	24 
path	of	the	trapping	beam.	Drug	particles	passing	across	the	side	viewing	window	were	illuminated	25 
by	 an	 LED	 and	 observed	 on	 a	monitor.	 Scattering	 of	 the	 unfiltered	 trapping	 laser	 from	 a	 trapped	26 
particle	was	viewed	on	the	same	monitor	to	indicate	the	positional	stability	of	the	particle.	27 
Based	 on	 the	 stated	 mass	 per	 release	 of	 each	 drug,	 the	 density	 of	 the	 solid	 material	 (Zhejiang	28 
NetSun	 Co.,	 Ltd.,	 2010),	 the	 assumption	 that	 an	 average	 particle	 is	 solid	 and	 has	 a	 volume	 of	29 
approximately	10µm3,	a	single	release	from	each	inhaler	is	estimated	to	deliver	106	to	107	particles	30 
to	the	chamber,	although	some	are	assumed	to	be	lost	by	impaction	onto	the	walls	of	the	chamber.	31 
A	single	trapped	particle	at	least	2µm	in	diameter	is	sufficient	to	generate	a	Raman	spectrum.	32 
2.5	SEM	imaging	33 
Each	 drug	was	 actuated	 onto	 a	 glass	 cover	 slip	 and	 coated	with	 10nm	gold	 particles	 in	 a	 Polaron	34 
SC7640	 sputter	 coater.	 The	 cover	 slips	were	attached	 to	Agar	Scientific	25mm	double	 sided	 sticky	35 
carbon	tabs	prior	to	imaging	on	a	Philips	XL30	ESEM	FEG.	[Haijie	says	–	more	detail?]	36 
2.6	Chemical	Structures	of	the	asthma	drugs	investigated	37 
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 1 
Figure	3	Chemical	structures	of	single	molecules	of	salbutamol	sulfate	(a),	salmeterol	xinafoate	(b),	2 
fluticasone	propionate	(c),	and	ciclesonide	(d)	3 
Salbutamol	 sulfate	 particles	 were	 generated	 from	 a	 Salamol	 brand	 inhaler	 by	 Ivax	 Chemicals	 ltd.	4 
Salbutamol	 sulfate	 contains	 several	 polar	 groups	 and	no	 long	 aliphatic	 chains,	 and	 its	 hygroscopic	5 
character	 was	 already	 documented	 (Tong,	 et	 al.,	 2014).	 Salmeterol	 xinafoate	 particles	 were	6 
produced	from	a	“Serevent”	brand	inhaler	produced	by	Cipla	Ltd.	Salmeterol	also	contains	multiple	7 
polar	 groups	 but	 also	 a	 long	 aliphatic	 chain.	 Its	 hygroscopic	 properties	 are	 to	 be	 determined.	8 
	9 
Fluticasone	 propionate,	 generated	 from	 a	 “flixotide”	 brand	 inhaler,	 is	 manufactured	 by	10 
GlaxoSmithKline,	 and	 ciclesonide	 particles	 were	 generated	 by	 a	 “Ciclohale”	 brand	 inhaler	 also	 by	11 
Cipla	 Ltd.	 Ciclesonide	 is	 produced	 under	 license	 from	 Takeda	UK	 Ltd.	 Fluticasone	 propionate	 and	12 
ciclesonide	are	both	steroids	and	as	such	are	relatively	hydrophobic	and	are	not	expected	to	show	13 
hygroscopic	properties.	14 
3. Results	and	Discussion	15 
3.1	Thermodynamic	Calculations	of	Particle	Hygroscopicity	16 
Using	 E-AIM	 to	 predict	 the	 hygroscopic	 properties	 of	 the	 drug	 molecules	 (Clegg,	 et	 al.,	 2001)	17 
(Engelhart,	et	al.,	2011)	(Ling	&	Chan,	2008)	yielded	two	distinct	types	of	interaction	(figure	4).	The	18 
beta-2	 agonists	 contain	 a	 higher	 proportion	 of	 hydrophilic	 groups	 and	 are	 thus	 expected	 to	 be	19 
strongly	hygroscopic,	while	the	more	lipophilic	steroids	are	expected	to	collect	little	water	from	the	20 
air	 even	 under	 near-100%	 RH	 conditions.	 However,	 this	 does	 not	 take	 into	 account	 the	 crystal	21 
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structure	 of	 solid	 particles	 which	 may	 block	 access	 to	 hydrophilic	 sites	 and	 prevent	 otherwise	1 
hydrophilic	molecules	from	interacting	with	water	in	the	air.	2 
	3 
	 Figure	4	Influence	of	humidity	on	particle	diameter	predicted	from	chemical	bonding	 	4 
3.2	Drug	Particle	Crystallography	5 
The	Mercury	 3.6	 program	 (Macrae,	 et	 al.,	 2006)	was	 used	 to	 simulate	 the	 crystal	 structure	 of	 all	6 
drugs	whose	structures	had	been	added	to	the	Cambridge	Structural	Database	run	by	the	Cambridge	7 
Crystallographic	Data	Centre	(CCDC,	2015).	8 
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 1 
Figure	5	Model	unit	cells	of	salbutamol	sulfate	(a),	fluticasone	propionate	(b),	and	ciclesonide	(c).	Salmeterol	xinafoate's	2 
unit	cell	was	not	available	at	time	of	writing.	Hydrogen	bonding	within	the	unit	cell	is	illustrated	with	a	cyan	line,	while	3 
hydrogen	bonding	external	to	the	unit	cell	(thus	contributing	to	hygroscopic	behaviour)	are	illustrated	with	red	lines.	4 
The	chemical	structure	of	salbutamol	sulfate	(figure	5a)	shows	hydrophilic	sites	across	the	molecule,	5 
which	are	indicated	in	Figure	5	as	red	lines	symbolizing	hydrogen	bonding	capability	of	the	structure.	6 
The	most	likely	crystal	form	generated	by	rapid	solvent	evaporation	in	air	was	first	described	in	1978	7 
(Leger,	et	al.,	1978),	with	an	8	molecule	unit	cell	 (figure	5a)	that	shows	hydrogen	bonding	sites	on	8 
every	 face.	 Hygroscopic	 behaviour	 is	 inferred	 from	 this	 structure	 and	 has	 been	 demonstrated	 in	9 
previous	experiments	at	room	temperature	(Tong,	et	al.,	2014).	10 
Salmeterol	 is	 not	 found	 in	 the	 Cambridge	 Structural	 Database.	 Solid	 structures	 are	 variously	11 
described	 as	 either	 amorphous,	 or	 needle-like	 or	 plate-like	 crystals	 depending	 on	 the	 exact	12 
conditions	of	manufacture	 (York	&	Hanna,	 1994)	 (Barjoan	&	Clotet,	 2009).	 Salmeterol	 xinafoate	 is	13 
bound	together	by	hydrogen	bonding	of	the	δ-positive	amine	group	on	salmeterol	to	the	δ-negative	14 
carboxylic	acid	group	on	 the	xinafoic	acid.	The	 two	groups	are	expected	 to	 cancel	 their	 respective	15 
charges,	 leaving	few	hydrophilic	sites	open	to	 interaction	with	water	while	the	particle	 is	 in	a	solid	16 
state.	17 
As	 a	 steroid,	 fluticasone	 is	 expected	 to	 be	 lipophilic	 (Lipworth	&	 Jackson,	 2000).	 The	 structure	 of	18 
fluticasone	 (figure	 5b)	 does	 have	 a	 number	 of	 polar	 groups.	 However,	 the	 documented	 crystal	19 
structure	(Cejka,	et	al.,	2005)	describes	a	plate-like	structure	with	any	hydrogen	bonding	occurring	20 
along	 the	plane	of	growth	 (figure	5b)	 resulting	 in	water	 interaction	only	along	edges,	and	 likely	 to	21 
result	in	little	or	no	hygroscopic	behaviour.	22 
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Ciclesonide	(figure	5c)	is	found	as	either	needle-like	(Phull,	et	al.,	2012)	or	needle-like	and	spherulitic	1 
crystals	as	well	as	amorphous	solids	(Feth,	et	al.,	2007)	depending	on	solvent	type	and	evaporation	2 
time.	Ciclesonide	has	multiple	polar	groups	but	 the	model	unit	cell	described	by	Feth	et	al.	 (2007)	3 
describes	most	of	the	oxygens	arranged	inside	the	crystal	with	the	hydrophobic	sites	facing	outward.	4 
Limited	hydrogen	bonding	due	to	the	hydroxyl	and	ketone	groups	on	adjacent	molecules	have	the	5 
potential	to	attract	water	molecules	to	crystal	faces,	but	the	hydrophobic	nature	of	the	rest	of	the	6 
exposed	molecule	implies	that	hygroscopic	behaviour	is	unlikely.	7 
3.3	SEM	imaging	and	Trapping	Logistics	8 
 9 
Figure	6	SEM	images	of:	(a)	salbutamol	sulphate,	(b)	salmeterol	xinafoate,	(c)	fluticasone	propionate	&	(d)	ciclesonide	10 
The	 likelihood	of	a	particle	being	successfully	trapped	was	dictated	by	both	particle	shape	and	the	11 
number	of	particles	generated	per	release.	Salbutamol	sulfate	had	been	optically	trapped	previously	12 
on	the	same	apparatus	(Tong,	et	al.,	2014).	The	thick,	needle	like	shape	of	salbutamol	particles	(fig	13 
6a)	is	well	suited	to	entrapment	for	reasons	detailed	in	section	2.4,	and	the	100µg	per	release	dose	14 
of	the	available	 inhalers	resulted	 in	a	successfully	suspended	particle	roughly	once	for	every	other	15 
release.	 Salmeterol	 xinafoate	was	 significantly	 harder	 to	 trap	 and	 retain	 than	 the	 others	 due	 to	 a	16 
combination	 of	 its	 low	 dose	 (20µg	 per	 release)	 and	 flat,	 platelike	 aggregate	 structure	 (fig	 6b).	17 
Fluticasone	has	a	similar	crystal	structure	to	salmeterol	but	a	much	higher	dose	(250µg	per	release)	18 
and	was	more	reliably	 trapped	than	salbutamol	sulfate	 (fig	6c).	Ciclesonide	was	similar	 in	 trapping	19 
efficiency	to	fluticasone	since	its	 lower	dose	(160µg	per	release)	was	balanced	by	a	more	spherical	20 
particle	shape	(fig	6d).	21 
3.4	Raman	spectrum	changes	from	hygroscopic	properties	and	additional	compounds	22 
12 
 
Hydrogen	bonding	with	water	molecules	adjacent	to	the	polar	groups	of	organic	molecules	expands	1 
the	 range	 of	 vibrational	 energy	 states	 that	 can	 generate	 Raman	 scattering	 photons.	 This	 effect	2 
allows	water	uptake	by	hygroscopic	particles	to	be	monitored	by	Raman	spectroscopy.	3 
All	 four	 drugs	 use	 hydrofluoroalkane	 HFA	 134a/Norflurane	 as	 a	 propellant.	 The	 salbutamol	 and	4 
ciclesonide	inhalers	also	report	anhydrous	ethanol	among	their	ingredients.	Norflurane	contains	four	5 
C-F	bonds,	each	of	which	generate	a	distinctive	Raman	scattering	peak	at	1234	cm-1.	This	peak	is	not	6 
expected	to	be	visible	in	the	Raman	spectra	of	the	drug	molecules,	apart	from	Fluticasone	which	has	7 
3	C-F	bonds	of	 its	own,	due	to	Norflurane’s	 low	boiling	point	(-26.5oC,	(Lide,	1991))	at	atmospheric	8 
pressure	 causing	 all	 of	 the	 propellant	 to	 boil	 off	 before	 readings	 can	 be	 collected.	 The	 spectra	9 
collected	from	particles	other	than	fluticasone	do	not	show	peaks	in	the	C-F	stretching	region,	which	10 
implies	that	all	propellant	boils	off	before	the	particles	are	scanned.	11 
3.5	Salbutamol	sulfate	/	Salamol™	12 
3.5a	Raman	spectra	and	structural	information	13 
Salbutamol	 sulfate	 contains	 fewer	 distinctive	 functional	 groups	 than	 the	 other	 drugs.	 Each	14 
salbutamol	molecule	contains	a	single	phenol	group,	two	aliphatic	hydroxyls	and	a	secondary	amine.	15 
One	molecule	 of	 salbutamol	 contains	 two	 ionised	 salbutamol	molecules	 bound	 to	 a	 single	 sulfate	16 
group.	The	S=O	symmetric	stretches	on	the	sulfate	show	a	small	but	distinctive	peak	at	1154	cm-1.	17 
The	largest	peaks	in	the	salbutamol	spectrum	correspond	to	–CH	wagging	at	656	cm-1,	aromatic	ring	18 
vibration	at	752	cm-1,	C-C-O	stretches	in	relation	to	the	aliphatic	hydroxyls	at	784	cm-1,	asymmetric	19 
hydroxyl	 stretches	 at	 969,	 977	 and	 1008	 cm-1,	 phenyl	 ring	 vibrations	 at	 1059	 and	 1074cm-1,	 a	20 
prominent	CH	stretch	at	1257cm-1	(this	bond	can	be	found	in	figure	3a	just	above	the	ring)	CH2	and	21 
CHOH	vibrations	again	from	the	aliphatic	hydroxyls	at	1360	cm-1,	a	broad	ring	stretching	peak	around	22 
1450cm-1	 followed	 by	 a	 CH2-N	 amine	 peak	 at	 1463cm-1,	 and	 finally	 a	 strong	 peak	 at	 1615cm-1	23 
corresponding	to	the	phenolic	C-OH	stretch.	These	peaks	correspond	to	those	found	in	the	literature	24 
(Ali,	et	al.,	2009).		25 
3.5b	Impact	of	RH	and	Temperature	on	salbutamol	spectra	26 
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 1 
Figure 5 Raman spectra of optically trapped salbutamol sulfate particles at a range of RH and temperatures 2 
RH	above	92%,	 the	deliquescence	point	 identified	by	Tong	et	al.	 (Tong,	et	al.,	2014),	 could	not	be	3 
maintained	 at	 physiological	 temperature	 (37oC)	 with	 the	 available	 equipment,	 so	 measurements	4 
were	taken	at	30oC-	 the	highest	 temperature	at	which	>92%	RH	could	be	maintained.	The	particle	5 
trapped	at	98%	RH	and	30	oC	was	small,	hence	the	poorer	signal/noise	ratio.	The	contrast	between	6 
the	 relatively	 dry	 and	 relatively	wet	 particles	 is	 clear	 to	 see	 as	 the	 peaks	 of	 the	wet	 particles	 are	7 
broader,	and	some	peaks	such	as	the	hydroxyl	peak	at	1008cm-1	and	the	amine	peak	at	1463cm-1	are	8 
more	pronounced.	The	more	pronounced	peak	around	the	aliphatic	hydroxyl	stretches	near	800cm-1	9 
is	the	result	of	an	overlapping	fluorescence	signal	seen	in	aqueous	solutions	of	salbutamol	(Dodson,	10 
et	al.,	2011)	(Pandya,	et	al.,	2010)	and	is	consistent	with	Tong	et	al’s	findings	(Tong,	et	al.,	2014).	11 
The	spectral	traces	of	similar	RH	but	contrasting	temperature	are	very	similar.	This	implies	that	the	12 
temperature	 difference	 from	 the	 open	 air	 to	 inside	 the	 user’s	 body	 is	 not	 great	 enough	 to	 cause	13 
changes	 in	 the	 hygroscopic	 properties	 of	 Salbutamol.	 Relative	 humidity	 is	 thus	 shown	 to	 be	 the	14 
major	factor	controlling	the	particle’s	hygroscopicity.	15 
3.6	Salmeterol	xinafoate	/	Serevent™	16 
3.6a	Raman	spectra	and	structural	information	17 
Salmeterol	xinafoate	contains	several	aromatic	rings,	an	ether	group,	a	benzoic	acid	and	a	secondary	18 
amine.	Benzoic	acid	 is	distinct	 from	both	aromatic	 rings	and	carboxylic	acids	due	 to	 the	 increased	19 
conjugation	(Kwon,	et	al.,	1994)	and	shows	distinctive	peaks	in	the	solid	state	at	1627	cm-1,	994	cm-1	20 
and	 788	 cm-1.	 These	 peaks	 are	 all	 present	 in	 our	 spectra	 (see	 figure	 7).	 Ring	 stretches	 are	 clearly	21 
visible	at	1580-1616	cm-1,	1400-1420	cm-1	(the	multiple	strong	peaks	denoting	ring	stretches	shifted	22 
by	the	various	adjacent	functional	groups)	and	symmetric	ring	stretches	are	visible	at	1000-1028	cm-23 
1,	1215	and	1257	cm-1.	A	strong	amine	vibration	peak	is	visible	at	1204	cm-1.	A	sharp	peak	at	730	cm-1	24 
corresponds	to	rotational	peaks	from	CH2	groups,	as	would	be	expected	by	a	molecule	with	a	 long	25 
14 
 
aliphatic	chain	like	salmeterol.	The	ether	group	can	be	identified	by	small	peaks	at	554	and	1145	cm-1 
1.	These	spectra	correspond	well	with	previously	published,	well-defined	Raman	spectra	(Ali,	et	al.,	2 
2008a).	3 
3.5b	Impact	of	RH	on	salmeterol	spectra	4 
 5 
Figure 7 Raman spectra of salmeterol xinafoate at a range of RH values 6 
The	 hygroscopic	 behaviour	 of	 salmeterol	 xinafoate	 predicted	 by	 E-AIM	may	 be	 limited	 by	 stearic	7 
hindrance	of	the	hydrophilic	sites	by	hydrophobic	structures	arranged	around	them	in	solid	crystals.	8 
Salmeterol	xinafoate	does	not	demonstrate	any	visible	broadening	around	peaks	corresponding	 to	9 
either	 salmeterol’s	 amine	 group	or	 the	 carboxylic	 acid	 group	on	 its	 xinafoic	 acid	partner	upon	RH	10 
enhancement.	 However,	 the	 relative	 enhancement	 of	 peaks	 corresponding	 to	 aromatic	 ring	11 
stretches	at	650,	1000	and	1580	cm-1	 imply	some	interaction	with	water	around	some	or	all	of	the	12 
aromatic	rings	in	salmeterol	xinafoate	at	>88%	RH.	13 
3.4	Fluticasone	propionate	/	Flixotide	14 
3.4a	Raman	spectra	and	structural	information	15 
Fluticasone	 contains	 several	 distinctive	 bonding	 types	 that	would	 be	 expected	 to	 yield	 distinctive	16 
peaks	in	any	resulting	Raman	spectra:	a	phenone,	an	ester,	a	thioether	and	three	C-F	bonds	across	17 
the	 molecule.	 Fluticasone	 has	 been	 imaged	 by	 Raman	 spectroscopy	 previously	 and	 its	 spectra	18 
interpreted	in	depth	(Ali,	et	al.,	2008b)	(Rogueda,	et	al.,	2011)	(Theophilus,	et	al.,	2006)	(Wang,	et	al.,	19 
2014),	which	provides	useful	references	for	the	spectra	generated	here.	20 
The	most	distinctive	aspect	of	our	fluticasone	spectrum	was	the	sharp	peak	at	640	-	650	cm-1.	The	21 
peak	 overlaps	 the	 thiocarboxylic	 ester	 peak	 found	 at	 646cm-1	 in	 the	 literature	 (Coates,	 2000)	22 
(Bloxham,	et	al.,	2002),	but	was	much	more	intense	and	varied	in	intensity	across	different	particles.	23 
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This	 peak	was	 believed	 to	 be	 a	 result	 of	 a	 second	 harmonic	 resonance	 effect	 from	 the	 1064	 nm	1 
trapping	laser,	as	a	532	nm	excitation	would	result	in	a	resonance	peak	at	639.5	cm-1.	2 
Repeated	measurements	of	fluticasone	particles	on	a	coverslip	with	the	1064	nm	trapping	laser	off	3 
did	not	show	the	peak	in	the	Raman	spectrum,	and	the	peak	did	not	appear	when	the	1064nm	laser	4 
was	 turned	 on	 at	 powers	 equivalent	 to	 those	 used	 in	 the	 optical	 trap.	However,	 at	 higher	 power	5 
outputs	the	same	peak	observed	in	trapped	particles	began	to	appear	and	to	dominate	the	Raman	6 
spectrum.	The	resonance	peak	is	stronger	in	symmetrical	particles	that	are	more	likely	to	be	stably	7 
trapped	so	more	pronounced	peaks	in	the	Raman	spectra	of	trapped	fluticasone	are	to	be	expected.		8 
The	 spectra	 shown	 in	 figure	 8	 have	 had	 the	 640-650	 cm-1	 region	 normalised	 to	 remove	 the	9 
resonance	peak.	10 
The	strongest	peak	in	the	spectrum	of	fluticasone	is	the	C=O	vibration	at	1659cm-1,	followed	by	the	–11 
CH3	symmetric	stretch	(there	are	4	–CH3	groups	in	Fluticasone)	at	1606cm-1.	–CH2	and	–CH	stretches	12 
occur	at	around	1380	and	1330	cm-1	respectively	and	highly	distinctive	C-F	and	S-C-F	bands	occur	at	13 
1234cm-1	 and	 1022cm-1.	 As	 expected,	 this	 was	 the	 only	 compound	 that	 exhibited	 scattering	14 
consistent	with	C-F	bonds,	implying	that	in	all	samples	the	Norflurane	propellant	had	boiled	off	prior	15 
to	analysis.	The	phenone	group	registers	as	an	OOH/CCH	aromatic	deformation	peak	at	888cm-1.	A	16 
small	C-H	wagging	peak	can	be	seen	at	around	700cm-1.	17 
3.4b	Impact	of	RH	on	fluticasone	spectra	18 
 19 
Figure 8 Raman spectra of fluticasone propionate at a range of RH values 20 
The	spectrum	collected	at	80%	RH	was	from	a	small	particle-	around	1µm	in	diameter.	This	accounts	21 
for	the	greater	noise	in	the	signals.	Otherwise,	no	peaks	are	displaced	or	strongly	deformed	by	the	22 
rise	in	relative	humidity.	23 
16 
 
3.5	Ciclesonide	/	Alvesco™	1 
3.5a	Raman	spectra	and	structural	information	2 
Ciclesonide	 (Feth,	 et	 al.,	 2008)	 has	 a	 diverse	 selection	 of	 functional	 groups,	 which	 generates	 a	3 
complicated	Raman	spectrum.	The	largest	peak	at	1654cm-1	represents	the	stretching	vibration	of	an	4 
α,	β-unsaturated	carbonyl,	while	the	adjacent	peak	at	1601cm-1	shows	the	neighbouring	C=C	bond.	5 
Ciclesonide	contains	four	-CH3	groups	and	this	corresponds	to	another	large,	broad	peak	at	1443cm-6 
1.	 The	 three	 ether	 bonds	 generate	 another	 large	 peak	 at	 1112cm-1,	 and	 the	 single	 ester	 linkage	7 
appears	at	1242cm-1.	Ciclesonide	has	a	single	hydroxyl	group	attached	to	a	six-membered	saturated	8 
ring,	 and	 a	 matching	 “cyclic	 alcohol”	 stretch	 appears	 at	 1029cm-1.	 The	 C-C	 stretches	 of	 the	 two	9 
saturated	 six-membered	 rings	 are	 found	 at	 963cm-1.	 Multiple	 small	 peaks	 around	 800-900cm-1	10 
represent	ring	deformation	 in	the	phenol	group	adjacent	to	the	saturated	rings.	Another	region	of	11 
small	peaks	around	1330cm-1	corresponds	to	the	various	symmetric	and	antisymmetric	stretches	of	12 
the	isopropyl	group.	13 
3.5b	Impact	of	RH	and	Temperature	on	Ciclesonide	Spectra	14 
 15 
Figure 9 Raman spectra of ciclesonide at a range of RH values 16 
As	a	steroid,	ciclesonide	is	not	very	hydrophilic	and	does	not	contain	many	polar	groups.	The	crystal	17 
structure	 shows	 very	 little	opportunity	 for	water	uptake	on	 surfaces.	 It	would	not	be	expected	 to	18 
show	hygroscopic	behaviour,	 and	no	 such	behaviour	was	observed	as	all	Raman	spectra	 shown	 in	19 
Figure	9	show	not	changes	from	low	to	high	humidities	between	50-98%	RH.	20 
4.	Conclusions	21 
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The	Raman	spectra	of	four	optically	trapped	drug	particles	(salbutamol	sulfate,	salmeterol	xinafoate,	1 
fluticasone	 propionate	 and	 ciclesonide)	 were	 measured	 within	 a	 model	 lung.	 The	 model	 lung	2 
allowed	for	modification	of	local	relative	humidity	(RH)	to	test	the	drugs	for	hygroscopic	behaviour,	3 
while	the	optical	trap	eliminated	any	potential	surface	artefacts	from	water	droplets	forming	around	4 
a	 solid	 particle	 on	 a	 cover	 slip.	 Raman	 spectroscopy	 allowed	 for	 the	 direct	 observation	 of	 the	5 
hydrogen	 bonding	 with	 water	 in	 hydrophilic	 groups,	 where	 the	 broadening	 of	 peaks	 indicates	6 
hygroscopicity.	7 
The	 hygroscopic	 properties	 of	 salmeterol,	 fluticasone	 and	 ciclesonide	 are	 not	 influenced	 to	 a	8 
measurable	 degree	 by	 changes	 in	 RH	 from	 30%	 (similar	 to	 the	 open	 air	 in	 average	 weather	9 
conditions)	 to	 93-95%	 at	 295oK	….	 .	 Future	 experiments	will	 discern	whether	 biologically	 relevant	10 
temperatures	and,	ideally,	RH	values	closer	to	100%	trigger	deliquescence	and	over	what	timescale.	11 
The	observed	 fluorescence	 effects	 of	 the	Raman	 laser	 on	 salmeterol	 xinafoate	may	be	 avoided	 in	12 
future	by	using	a	longer	excitation	wavelength	Raman	probe.	13 
Salbutamol	 sulfate	 particles,	 meanwhile,	 are	 affected	 by	 changes	 in	 RH	 and	 change	 size	 when	14 
exposed	 to	 very	 humid	 air.	 Thus	 a	 reduction	 in	 average	 particle	 size	 at	 the	 point	 of	manufacture	15 
based	 on	 the	 hydrated	 rather	 than	 dry	 diameter	 might	 yield	 the	 same	medical	 response	 from	 a	16 
lower	dose.	17 
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